TCGA-PK-A5HB-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.515
- E2F_TARGETS+0.464
- MITOTIC_SPINDLE+0.366
- MYC_TARGETS_V1+0.361
- PROTEIN_SECRETION+0.340
- ANGIOGENESIS+0.230
- UV_RESPONSE_DN+0.208
- MYC_TARGETS_V2+0.202
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.181
- UNFOLDED_PROTEIN_RESPONSE+0.173
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.359
- INTERFERON_ALPHA_RESPONSE-0.275
- ALLOGRAFT_REJECTION-0.272
- INTERFERON_GAMMA_RESPONSE-0.265
- P53_PATHWAY-0.263
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.245
- BILE_ACID_METABOLISM-0.214
- FATTY_ACID_METABOLISM-0.139
- OXIDATIVE_PHOSPHORYLATION-0.125
- UV_RESPONSE_UP-0.121
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4SCWT0FX | EPN | EPN Tumor | 0.802 |
| 2 | SRR25043635 | — | — | 0.772 |
| 3 | 5572a203-73b9-4a85-b47d-af228abca5b1 | — | — | 0.769 |
| 4 | MNG289 | — | — | 0.762 |
| 5 | ERR2598197 | fetal | fetal | 0.756 |
| 6 | TCGA-60-2703-01A-11R-2045-07 | — | cohortSQ1 | 0.750 |
| 7 | ERR2598184 | fetal | fetal | 0.743 |
| 8 | ERR2598169 | fetal | fetal | 0.742 |
| 9 | ERR2598171 | fetal | fetal | 0.736 |
| 10 | R156 | — | — | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.515 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.464 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.366 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.361 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.208 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.202 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.181 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.173 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.155 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.149 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.147 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.103 | Inavolisib | — uncovered |
| HYPOXIA | 0.101 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.094 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.077 | Inavolisib | — uncovered |
| COAGULATION | 0.074 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.073 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.069 | Temsirolimus | — uncovered |